Clinical Trials Directory

Trials / Completed

CompletedNCT06168877

Use of Integrated PET/CT as a First Line Staging and Re-staging Technique in Oncologic Patient.

Status
Completed
Phase
Study type
Observational
Enrollment
30 (actual)
Sponsor
IRCCS San Raffaele · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers

Summary

Positron emission tomoscintigraphy (PET) and contrast computed tomography (CTmdc) are diagnostic methods widely used in the staging and restaging of neoplastic diseases. In recent years, PET tomographs have been implemented, integrating a CT scanner into the PET tomograph (PET/CT): these tomographs are able to simultaneously acquire the function/metabolism study (PET) and the morgfostructural study (CT). Numerous clinical studies have demonstrated the added diagnostic value of PET/CT compared to PET with consequent effect on the choice of treatment type. In addition to the potential clinical value deriving from the simultaneous execution of the two diagnostic methods, it is necessary to consider the possibility of a reduction in indirect costs deriving from the reduction of days of work lost and costs related to transport, both for the patient and for any companions. The aims of this multicenter observational study are: 1. evaluate the diagnostic accuracy of PET/CT, contrast-enhanced CT and contrast-enhanced PET/CT+CT performed in a single examination session (single staging) in cancer patients (patients suffering from lymphoma and lung cancer). 2. evaluate any psychological, quality of life and economic benefits deriving from carrying out the two diagnostic procedures in a single examination session.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTExecution of 18F-FDG PET/CT and contrast-enhanced CT scan.PET/CT, contrast-enhanced CT and contrast-enhanced PET/CT+CT performed in a single examination session (single staging) in cancer patients (patients suffering from lymphoma and lung cancer).

Timeline

Start date
2009-10-21
Primary completion
2014-07-03
Completion
2014-07-03
First posted
2023-12-13
Last updated
2023-12-13

Source: ClinicalTrials.gov record NCT06168877. Inclusion in this directory is not an endorsement.